The analysis of effectiveness and cost of lamivudine in treatment of chronic hepatitis

Objective:To analyze the effect,side effects and cost of lamivudine in treatment of chronic hepatitis.Methods:102 patients with chronic hepatitis whose values of ALT≥120IU·L -1 were divided into lamivudine group( n =34),interferon group( n =33) and the group treated with the protect liver and lower aminotransferase drugs.The patients treated for more than 6 months were detected the serum HBV DNA and HBeAg as anti viral parameter,ALT and the improvement of clinical symptom as effective parameter,and the comparison of drug cost effectiveness as pharmaco economic parameter.Results:There were no significant differences in ALT and the improvement of clinical symptom between lamivudine group and the other two,the effective rate were 88.24%,78.79%, 82.86% respectively.The HBV DNA negative turning rate in lamivudine group was obviouly bigger than those in the other two,the rate were 88.2%,39.4%,11.4% respectively.The HBeAg negative turning rate in lamivudine group was similar to that in interferon group(26.5% vs 24.2%),and was significantly bIgger than that in the group treated with the protect liver and lower aminotrausferase drugs(11.4%).Interferon group had more side effects(25/33) than the other two.The medical expenditure was that interferon groupthe group treated with the protect liver and lower aminotransferase drugslamivudine group.Conclusion:Lamivadine is effective and economical in treatment of chronic hepatitis.